Two months after a hefty capital raise signaled a prospective shopping spree for Onyx Pharmaceuticals Inc., the Emeryville, Calif.-based firm snatched up Proteolix Inc. in a potential $851 million deal centered on carfilzomib, a proteasome inhibitor poised to take on Velcade (bortezomib) in the multiple myeloma space. (BioWorld Today) Read More
